Summary
Global Markets Direct’s, ‘Ocular Hypertension - Pipeline Review, H1 2016’, provides an overview of the Ocular Hypertension pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Ocular Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Ocular Hypertension
- The report reviews pipeline therapeutics for Ocular Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Ocular Hypertension therapeutics and enlists all their major and minor projects
- The report assesses Ocular Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Ocular Hypertension
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Ocular Hypertension
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ocular Hypertension pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Aerie Pharmaceuticals, Inc.
Allergan Plc
Amakem NV
Asahi Kasei Pharma Corp.
Bausch & Lomb Incorporated
Can-Fite BioPharma Ltd.
D. Western Therapeutics Institute, Inc.
F. Hoffmann-La Roche Ltd.
Inotek Pharmaceuticals Corporation
Kowa Company, Ltd.
Lee's Pharmaceutical Holdings Limited
NicOx S.A.
Ocular Therapeutix, Inc.
Ono Pharmaceutical Co., Ltd.
Otsuka Holdings Co., Ltd.
pSivida Corp.
Sanofi
Santen Pharmaceutical Co., Ltd.
Senju Pharmaceutical Co., Ltd.
Sylentis S.A.U.
ViSci Ltd.
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Ocular Hypertension Overview 10
Therapeutics Development 11
Pipeline Products for Ocular Hypertension - Overview 11
Pipeline Products for Ocular Hypertension - Comparative Analysis 12
Ocular Hypertension - Therapeutics under Development by Companies 13
Ocular Hypertension - Therapeutics under Investigation by Universities/Institutes 15
Ocular Hypertension - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Ocular Hypertension - Products under Development by Companies 19
Ocular Hypertension - Products under Investigation by Universities/Institutes 21
Ocular Hypertension - Companies Involved in Therapeutics Development 22
Aerie Pharmaceuticals, Inc. 22
Allergan Plc 23
Amakem NV 24
Asahi Kasei Pharma Corp. 25
Bausch & Lomb Incorporated 26
Can-Fite BioPharma Ltd. 27
D. Western Therapeutics Institute, Inc. 28
F. Hoffmann-La Roche Ltd. 29
Inotek Pharmaceuticals Corporation 30
Kowa Company, Ltd. 31
Lee's Pharmaceutical Holdings Limited 32
NicOx S.A. 33
Ocular Therapeutix, Inc. 34
Ono Pharmaceutical Co., Ltd. 35
Otsuka Holdings Co., Ltd. 36
pSivida Corp. 37
Sanofi 38
Santen Pharmaceutical Co., Ltd. 39
Senju Pharmaceutical Co., Ltd. 40
Sylentis S.A.U. 41
ViSci Ltd. 42
Ocular Hypertension - Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Combination Products 44
Assessment by Target 45
Assessment by Mechanism of Action 47
Assessment by Route of Administration 49
Assessment by Molecule Type 51
Drug Profiles 53
(carteolol hydrochloride + latanoprost) - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
(dorzolamide hydrochloride + latanoprost) - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
(latanoprost + netarsudil mesylate) - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
(latanoprost + trabodenoson) - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
(tafluprost + timolol maleate) - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
AMA-0076 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
ATS-8535 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
bamosiran - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
bimatoprost - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
bimatoprost SR - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
DE-117 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Gene Therapy for Steroid Induced Glaucoma and Ocular Hypertension - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
H-1129 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
latanoprost - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
latanoprost - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
latanoprost SR - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
latanoprost SR - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
latanoprost SR - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
latanoprostene bunod - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
levobetaxolol hydrochloride - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
NCX-470 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
NCX-667 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
netarsudil mesylate - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
ONO-9054 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
OPA-6566 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
piclidenoson - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
RG-4929 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
ripasudil - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
RO-5093151 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
SAR-366234 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
SNJ-1656 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
trabodenoson - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
travoprost SR - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Ocular Hypertension - Recent Pipeline Updates 96
Ocular Hypertension - Dormant Projects 114
Ocular Hypertension - Discontinued Products 116
Ocular Hypertension - Product Development Milestones 117
Featured News & Press Releases 117
Mar 03, 2016: Aerie Pharmaceuticals Announces Availability on Its Website of Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting 117
Feb 22, 2016: Aerie Pharmaceuticals Announces Four New Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting Next Week 117
Feb 17, 2016: Aerie Pharmaceuticals Reports Positive Rhopressa QD (netarsudil ophthalmic solution) 0.02% 12 Month Interim Safety Results for Rocket 2 118
Feb 16, 2016: Ocular Therapeutix Announces Phase 3 Clinical Development Plan for OTX-TP, an Innovative Therapy for Glaucoma and Ocular Hypertension 119
Oct 22, 2015: Ocular Therapeutix Reports on Topline Results of Phase 2b Glaucoma Clinical Trial 120
Oct 01, 2015: New Drug Application for Carteolol Hydrochloride/ Latanoprost, a Novel Combined Ophthalmic Solution, Submitted in Japan for the Treatment of Glaucoma and Ocular Hypertension 122
Sep 24, 2015: Aerie Pharmaceuticals Initiates Fourth Phase 3 Clinical Trial of Rhopressa 122
Sep 22, 2015: Bausch + Lomb and Nicox Announce FDA Acceptance of New Drug Application for Novel Glaucoma Candidate VESNEO (latanoprostene bunod) 123
Sep 21, 2015: Aerie Pharmaceuticals Initiates First Phase 3 Registration Trial of Roclatan 124
Sep 16, 2015: Aerie Pharmaceuticals Reports Positive Rhopressa Phase 3 Efficacy Results 125
Appendix 126
Methodology 126
Coverage 126
Secondary Research 126
Primary Research 126
Expert Panel Validation 126
Contact Us 126
Disclaimer 127
List of Tables
Number of Products under Development for Ocular Hypertension, H1 2016 11
Number of Products under Development for Ocular Hypertension - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 14
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Late Stage Development, H1 2016 16
Comparative Analysis by Clinical Stage Development, H1 2016 17
Comparative Analysis by Early Stage Development, H1 2016 18
Products under Development by Companies, H1 2016 19
Products under Development by Companies, H1 2016 (Contd..1) 20
Products under Investigation by Universities/Institutes, H1 2016 21
Ocular Hypertension - Pipeline by Aerie Pharmaceuticals, Inc., H1 2016 22
Ocular Hypertension - Pipeline by Allergan Plc, H1 2016 23
Ocular Hypertension - Pipeline by Amakem NV, H1 2016 24
Ocular Hypertension - Pipeline by Asahi Kasei Pharma Corp., H1 2016 25
Ocular Hypertension - Pipeline by Bausch & Lomb Incorporated, H1 2016 26
Ocular Hypertension - Pipeline by Can-Fite BioPharma Ltd., H1 2016 27
Ocular Hypertension - Pipeline by D. Western Therapeutics Institute, Inc., H1 2016 28
Ocular Hypertension - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 29
Ocular Hypertension - Pipeline by Inotek Pharmaceuticals Corporation, H1 2016 30
Ocular Hypertension - Pipeline by Kowa Company, Ltd., H1 2016 31
Ocular Hypertension - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016 32
Ocular Hypertension - Pipeline by NicOx S.A., H1 2016 33
Ocular Hypertension - Pipeline by Ocular Therapeutix, Inc., H1 2016 34
Ocular Hypertension - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 35
Ocular Hypertension - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 36
Ocular Hypertension - Pipeline by pSivida Corp., H1 2016 37
Ocular Hypertension - Pipeline by Sanofi, H1 2016 38
Ocular Hypertension - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2016 39
Ocular Hypertension - Pipeline by Senju Pharmaceutical Co., Ltd., H1 2016 40
Ocular Hypertension - Pipeline by Sylentis S.A.U., H1 2016 41
Ocular Hypertension - Pipeline by ViSci Ltd., H1 2016 42
Assessment by Monotherapy Products, H1 2016 43
Assessment by Combination Products, H1 2016 44
Number of Products by Stage and Target, H1 2016 46
Number of Products by Stage and Mechanism of Action, H1 2016 48
Number of Products by Stage and Route of Administration, H1 2016 50
Number of Products by Stage and Molecule Type, H1 2016 52
Ocular Hypertension Therapeutics - Recent Pipeline Updates, H1 2016 96
Ocular Hypertension - Dormant Projects, H1 2016 114
Ocular Hypertension - Dormant Projects (Contd..1), H1 2016 115
Ocular Hypertension - Discontinued Products, H1 2016 116
List of Figures
Number of Products under Development for Ocular Hypertension, H1 2016 11
Number of Products under Development for Ocular Hypertension - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 16
Comparative Analysis by Clinical Stage Development, H1 2016 17
Comparative Analysis by Early Stage Products, H1 2016 18
Assessment by Monotherapy Products, H1 2016 43
Assessment by Combination Products, H1 2016 44
Number of Products by Top 10 Targets, H1 2016 45
Number of Products by Stage and Top 10 Targets, H1 2016 45
Number of Products by Top 10 Mechanism of Actions, H1 2016 47
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 47
Number of Products by Routes of Administration, H1 2016 49
Number of Products by Stage and Routes of Administration, H1 2016 49
Number of Products by Molecule Types, H1 2016 51
Number of Products by Stage and Molecule Types, H1 2016 51
